3 Key Takeaways
Plain English Summary- 01Core Finding
Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38, thereby regulating DNA repair, epigenetic remodeling, and inflammatory signaling.
- 02Study Evidence
Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
What This Means for You
Importantly, the dependence of malignant cells on sustained NAD availability constitutes a therapeutically exploitable vulnerability. Accordingly, NAMPT inhibitors, PARP inhibitors, and strategies targeting NAD-consuming ectoenzymes have shown preclinical and, in select settings, clinical efficacy (real-world effectiveness in the trial).
Here, we critically review the rewiring of NAD metabolism in cancer, associated therapeutic opportunities, and barriers to their clinical exploitation.
The Discovery
Nicotinamide adenine dinucleotide (NAD) occupies a privileged position at the intersection of cellular bioenergetics, redox homeostasis, and signal transduction. Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38, thereby regulating DNA repair, epigenetic remodeling, and inflammatory signaling. Thus, NAD metabolism supports the preservation of cellular homeostasis against oncogenic insults. Malignant transformation, however, imposes substantial biosynthetic and genotoxic stress, often driving metabolic adaptations that amplify NAD production via nicotinamide phosphoribosyltransferase (NAMPT). This endows cancer cells with enhanced proliferative capacity, stress tolerance, and immunoevasive features.
How It Works, Simply
This endocrinology research focuses on inflammation · Immune response · Enzyme. Researchers evaluated it using a laboratory experimental model (Preclinical discovery) at the preclinical stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38, thereby regulating DNA repair, epigenetic remodeling, and inflammatory signaling.
- 02Study Evidence
Tested in a laboratory experimental model (preclinical discovery) at the preclinical stage.
- 03Practical Meaning
Early laboratory or animal model findings — human trials are still needed to confirm safety and benefit.
Biological Mechanism & Study Design
Study Design & Cohort
Laboratory research
Laboratory experimental model (Preclinical discovery) · Preclinical
Biological Pathway & Modality
Inflammation · Immune response · Enzyme
Intervention: A context-dependent framework for targeting NAD metabolism in cancer
Experimental Findings & Endpoints
Nicotinamide adenine dinucleotide (NAD) occupies a privileged position at the intersection of cellular bioenergetics, redox homeostasis, and signal transduction.
Beyond its canonical role in ATP synthesis, NAD serves as an obligate cofactor for enzymes including poly(ADP-ribose) polymerases (PARPs), sirtuins, and CD38, thereby regulating DNA repair, epigenetic remodeling, and inflammatory signaling. Thus, NAD metabolism supports the preservation of cellular homeostasis against oncogenic insults.
Malignant transformation, however, imposes substantial biosynthetic and genotoxic stress, often driving metabolic adaptations that amplify NAD production via nicotinamide phosphoribosyltransferase (NAMPT). This endows cancer cells with enhanced proliferative capacity, stress tolerance, and immunoevasive features.
Clinical Translation & Practice Context
Importantly, the dependence of malignant cells on sustained NAD availability constitutes a therapeutically exploitable vulnerability.
Accordingly, NAMPT inhibitors, PARP inhibitors, and strategies targeting NAD-consuming ectoenzymes have shown preclinical and, in select settings, clinical efficacy.
Here, we critically review the rewiring of NAD metabolism in cancer, associated therapeutic opportunities, and barriers to their clinical exploitation.
The Bottom Line · Clinical Pearl
“Here, we critically review the rewiring of NAD metabolism in cancer, associated therapeutic opportunities, and barriers to their clinical exploitation.”
Published in Cell Metabolism · Current Stage: Preclinical